0001104659-23-090262.txt : 20230811 0001104659-23-090262.hdr.sgml : 20230811 20230811114359 ACCESSION NUMBER: 0001104659-23-090262 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230811 DATE AS OF CHANGE: 20230811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TEKLA HEALTHCARE INVESTORS CENTRAL INDEX KEY: 0000805267 IRS NUMBER: 046564285 STATE OF INCORPORATION: MA FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 811-04889 FILM NUMBER: 231162341 BUSINESS ADDRESS: STREET 1: 100 FEDERAL STREET STREET 2: 19TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 6177728515 MAIL ADDRESS: STREET 1: 100 FEDERAL STREET STREET 2: 19TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 FORMER COMPANY: FORMER CONFORMED NAME: H&Q HEALTHCARE INVESTORS DATE OF NAME CHANGE: 19920703 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tekla Healthcare Opportunities Fund CENTRAL INDEX KEY: 0001604522 IRS NUMBER: 465317248 STATE OF INCORPORATION: MA FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 811-22955 FILM NUMBER: 231162343 BUSINESS ADDRESS: STREET 1: 100 FEDERAL STREET STREET 2: 19TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 617-772-8500 MAIL ADDRESS: STREET 1: 100 FEDERAL STREET STREET 2: 19TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 FORMER COMPANY: FORMER CONFORMED NAME: Tekla Healthcare Growth & Income Fund DATE OF NAME CHANGE: 20140402 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tekla World Healthcare Fund CENTRAL INDEX KEY: 0001635977 IRS NUMBER: 000000000 STATE OF INCORPORATION: MA FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 811-23037 FILM NUMBER: 231162342 BUSINESS ADDRESS: STREET 1: 100 FEDERAL STREET STREET 2: 19TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: (617) 772-8515 MAIL ADDRESS: STREET 1: 100 FEDERAL STREET STREET 2: 19TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TEKLA LIFE SCIENCES INVESTORS CENTRAL INDEX KEY: 0000884121 IRS NUMBER: 043147016 STATE OF INCORPORATION: MA FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 811-06565 FILM NUMBER: 231162344 BUSINESS ADDRESS: STREET 1: 100 FEDERAL STREET STREET 2: 19TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 6177728515 MAIL ADDRESS: STREET 1: 100 FEDERAL STREET STREET 2: 19TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 FORMER COMPANY: FORMER CONFORMED NAME: H&Q LIFE SCIENCES INVESTORS DATE OF NAME CHANGE: 19920929 DEFA14A 1 tm2323488d1_defa14a.htm DEFA14A

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

(Amendment No. __)

 

Filed by the Registrant x

Filed by a Party other than the Registrant ¨

 

Check the appropriate box:

 

¨ Preliminary Proxy Statement

 

¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

¨Definitive Proxy Statement

 

xDefinitive Additional Materials

 

¨Soliciting Material Pursuant to Sec. 240.14a-11(c) or Sec. 240.14a-12

 

Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, Tekla World Healthcare
Fund

(Name of Registrant as Specified In Its Charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

 

Payment of Filing Fee (Check the appropriate box):

 

xNo fee required.

 

¨Fee paid previously with preliminary proxy materials.

 

¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11

 

 

 

 

TEKLA HEALTHCARE INVESTORS

TEKLA LIFE SCIENCES INVESTORS

TEKLA HEALTHCARE OPPORTUNITIES FUND

TEKLA WORLD HEALTHCARE FUND

 

Please do not disregard this letter

 

Special Meeting of Shareholders EXPECTED TO BE ADJOURNED

WE NEED YOUR PARTICIPATION

 

Dear Shareholder:

 

We have been trying to reach you regarding the First Special Meeting of Shareholders of the above-mentioned Funds (the “Funds”). The Special Meeting of Shareholders was originally slated for August 14, 2023, but is expected to be adjourned until August 29, 2023 due to lack of shareholder participation. We are trying to reach the necessary participation for the meeting and still haven’t yet received your vote. You may think your vote is inconsequential, but your participation helps us to avoid costly additional adjournments and solicitations.

 

For meeting #1, shareholders are being asked to approve the proposal to approve new investment advisory agreements between the Funds and abrdn Inc, which is summarized below. The full proxy statement is available for your review here: www.OkapiVote.com/TeklaSpecial. Summary/benefits of the proposed new advisory agreements are:

 

·Tekla currently serves as the investment adviser to the Funds. Recently, Tekla entered into a purchase agreement with abrdn Inc. pursuant to which Tekla has agreed to sell certain assets to abrdn Inc. relating to Tekla’s advisory business for the Funds. 
·The Funds’ current investment team is currently expected to join abrdn Inc. as full-time employees and to continue managing the Funds after completion of the asset transfer.
·The Funds’ investment objectives and fundamental and non-fundamental policies will not change as a result of the new advisory agreements.
·The advisory fees of the Funds will not increase as a result of the new advisory agreements. abrdn will also seek to achieve savings through scale and efficiency in the Funds’ operations (for instance, by driving better terms from fund service providers). In addition, at a minimum, abrdn Inc. has contractually agreed to limit the Operating Expenses (as defined in the proxy statement) of each Fund to an amount that is at least 2bps less than the Funds’ current Operating Expenses.
·The opportunity to be part of a large and broad closed-end fund platform from a global and independent organization with a focus on continuing and expanding its asset management business in general and its U.S. registered closed-end fund business in particular.

 

While to date, an overwhelming majority of the votes received have been cast in favor of the Proposal, there are simply not sufficient shares voted to date to approve the Proposal for your Fund(s).

 

In order for your vote to be represented, we must receive your voting instructions. Even IF it is past the ORiginal INDICATED MEETING date, please submit your vote Today USING ONE OF THE FOLLOWING OPTIONS:

 

1.By Internet

Follow the simple instructions on the enclosed proxy card.

 

2.By Touchtone

Call the toll-free number located on your proxy card and follow the simple instructions.

 

3.By Mail

Sign, Date, and Return this proxy card using the enclosed postage-paid envelope

 

If possible, please use either of the first two options to ensure your vote is captured in time for the meeting. If you have any questions, please call Okapi Partners, the Funds’ proxy solicitor, toll-free at (877) 285-5990.

Representatives are available Monday - Friday 9:00am to 10:00pm (ET). Thank you for your continued support of the Funds and your assistance in this matter.